Medicine - Gastroenterology

Medicine & Life Sciences

1. Inflammatory Bowel Diseases 100%
2. Crohn Disease 89%
3. Ulcerative Colitis 70%
4. Colonoscopy 31%
5. Endoscopy 22%
6. vedolizumab 21%
7. Eosinophilic Esophagitis 19%
8. Therapeutics 18%
9. Colitis 18%
10. Colorectal Neoplasms 16%
11. Infliximab 16%
12. Safety 15%
13. Colon 14%
14. Neoplasms 13%
15. Polyps 13%
16. Pediatrics 12%
17. Placebos 11%
18. Gastroenterology 11%
19. Hemorrhage 10%
20. Irritable Bowel Syndrome 10%
21. Adalimumab 10%
22. Systematic Reviews 10%
23. Microbiota 9%
24. Gastroenterologists 9%
25. Confidence Intervals 9%
26. Capsule Endoscopy 9%
27. tofacitinib 9%
28. Coronavirus 9%
29. Ustekinumab 9%
30. Neuroendocrine Tumors 8%
31. Population 8%
32. Meta-Analysis 8%
33. Gastrointestinal Diseases 8%
34. Adenoma 8%
35. Inflammation 8%
36. Recurrence 8%
37. Biological Therapy 8%
38. Colectomy 8%
39. Colonic Neoplasms 7%
40. Tumor Necrosis Factor Inhibitors 7%
41. Clinical Trials 7%
42. Biological Products 7%
43. Incidence 7%
44. Cohort Studies 7%
45. Adrenal Cortex Hormones 7%
46. Child 7%
47. Fecal Microbiota Transplantation 7%
48. Biopsy 6%
49. Early Detection of Cancer 6%
50. Infections 6%
51. Multicenter Studies 6%
52. Pediatric Crohn's disease 6%
53. sialosyl-Tn antigen 6%
54. Odds Ratio 6%
55. Registries 5%
56. Pancreatic Neoplasms 5%
57. Physicians 5%
58. Quality of Life 5%
59. Mesalamine 5%
60. Pathologic Constriction 5%
61. Guidelines 5%
62. Adenomatous Polyps 5%
63. Steroids 5%
64. Leukocyte L1 Antigen Complex 5%
65. Adenocarcinoma 5%
66. Tumor Necrosis Factor-alpha 5%
67. Immunologic Factors 5%
68. Biomarkers 5%
69. Restorative Proctocolectomy 5%
70. Gastro-enteropancreatic neuroendocrine tumor 5%
71. Gastrointestinal Tract 5%
72. Endoscopic Retrograde Cholangiopancreatography 5%
73. Gastrointestinal Microbiome 5%